Oral JAK inhibitors for alopecia areata: FDA labels compared

Three oral JAK inhibitors have U.S. indications for severe alopecia areata: baricitinib, ritlecitinib, and deuruxolitinib [1][3][5]. They are not FDA-approved treatments for androgenetic hair loss or ordinary telogen shedding. Their labels also differ: baricitinib and deuruxolitinib are indicated for adults, while ritlecitinib includes adults and adolescents aged 12 years and older.

Each drug outperformed placebo in its own pivotal program [2][4][6][7]. There is no direct randomized trial among all three. Response percentages from separate programs cannot establish a hierarchy because trial duration, dose, participant mix, and analysis rules differ.

Alopecia areata is not pattern hair loss

Alopecia areata is an autoimmune disease that can produce patches of nonscarring hair loss or extensive scalp and body-hair loss. The pivotal oral JAK programs generally enrolled people with severe disease measured by the Severity of Alopecia Tool, often with at least 50% scalp hair loss [2][4][6][7].

Male and female pattern hair loss arise mainly from follicular miniaturization in an androgen-sensitive pattern. Telogen effluvium is a shedding process. These conditions can coexist, but a JAK-inhibitor indication for alopecia areata should not be transferred to them.

For those separate conditions, see our evidence reviews of male pattern hair loss and female pattern hair loss.

What do the three FDA labels cover?

All are oral kinase inhibitors, but they do not inhibit exactly the same targets. Baricitinib and deuruxolitinib inhibit JAK1 and JAK2 [1][5]. Ritlecitinib inhibits JAK3 and the TEC kinase family [3]. A mechanistic difference may affect dosing, interactions, and safety, but it does not predict an individual response without clinical evidence.

Baricitinib: the first U.S. systemic approval

BRAVE-AA1 and BRAVE-AA2 were randomized, double-blind, placebo-controlled phase 3 trials in adults with severe alopecia areata. The main outcome was a SALT score of 20 or less at week 36, meaning 20% or less scalp hair loss [2].

Both baricitinib doses studied outperformed placebo. At week 36, 38.8% and 35.9% of participants assigned to the FDA-labeled 4 mg dose reached SALT 20 or less in BRAVE-AA1 and BRAVE-AA2, compared with 6.2% and 3.3% assigned to placebo [2]. Many treated participants did not reach the endpoint. This is evidence of substantial scalp regrowth for a subset, not a guarantee of complete regrowth.

The trials were sponsored by Eli Lilly, and authors included company employees or disclosed financial relationships. The FDA label provides the approved dosing and risk framework; a journal graph should not be used by itself to choose a dose [1][2].

Ritlecitinib: an adolescent-inclusive label

The ALLEGRO phase 2b-3 trial enrolled participants aged 12 years and older with at least 50% scalp hair loss. It tested several ritlecitinib regimens against placebo for 24 weeks, followed by an extension period [4].

At week 24, 23% of participants assigned to 50 mg daily without a loading regimen reached SALT 20 or less, compared with 2% assigned to placebo [4]. ALLEGRO tested additional regimens, including loading-dose arms that are not the current U.S. regimen. The FDA-approved regimen should be read from the prescribing information [3].

The adolescent indication is an important distinction, but it does not mean that age is the only selection factor. Infection history, vaccination, laboratory values, other immunomodulators, pregnancy potential, and long-term treatment planning remain relevant [3].

A 2026 integrated analysis pooled up to approximately five years of ritlecitinib exposure. It reported serious adverse events in 6.8% of the pooled groups and described low exposure-adjusted rates for opportunistic infection, herpes zoster, malignancy excluding nonmelanoma skin cancer, and major cardiovascular events [8]. Pfizer employees were authors, and the analysis was descriptive without a long-term placebo group. More exposure helps characterize events; it does not cancel the boxed warning.

Deuruxolitinib: two adult phase 3 trials

THRIVE-AA1 and THRIVE-AA2 enrolled adults with severe, chronic alopecia areata and at least 50% scalp hair loss. Both randomized trials compared twice-daily deuruxolitinib regimens with placebo for 24 weeks [6][7].

In THRIVE-AA1, 29.6% of participants assigned to 8 mg twice daily reached SALT 20 or less, compared with 0.8% receiving placebo [6]. THRIVE-AA2 also favored both studied deuruxolitinib doses over placebo [7]. The FDA label approves 8 mg twice daily for adults and includes drug-interaction and pharmacogenetic restrictions that are specific to deuruxolitinib [5].

The 12 mg trial arm should not be presented as an approved U.S. option. Trial inclusion shows what researchers studied; the label determines the approved regimen.

Why cross-trial percentages do not rank the drugs

It is tempting to put the largest percentage at the top of a list. That would ignore several sources of bias:

• Baricitinib's primary assessment was at week 36, while the pivotal ritlecitinib and deuruxolitinib assessments were at week 24 [2][4][6][7].
• Regimens and dose-ranging structures differed.
• Baseline disease duration and proportions with alopecia totalis or universalis differed.
• Missing data, rescue treatment, and endpoint definitions can be handled differently.
• All programs were sponsor funded, with separate investigator networks.
• None randomized participants among all three FDA-approved drugs.

Indirect meta-analysis can generate a hypothesis, but it cannot replace a well-designed head-to-head trial.

Shared warnings, individual restrictions

All three labels carry boxed warnings involving serious infections, mortality, malignancy, major cardiovascular events, and thrombosis [1][3][5]. Much of the class warning context comes from another JAK inhibitor studied in an older rheumatoid arthritis population with cardiovascular risk factors [1][3][5]. That origin matters for interpretation, but the warnings still apply to the labeled products.

Pre-treatment and ongoing requirements vary by label. They can include infection and tuberculosis assessment, blood counts, liver or kidney considerations, lipid monitoring, vaccination review, drug-interaction checks, and pregnancy counseling [1][3][5]. Deuruxolitinib also has a CYP2C9-related restriction and interaction considerations that should not be copied to the other two drugs [5].

Long-term treatment raises practical questions about maintaining regrowth and what happens after stopping. Extension studies provide some information, but withdrawal and relapse are not answered identically for every drug or patient.

Bottom line

Baricitinib, ritlecitinib, and deuruxolitinib are FDA-approved oral JAK inhibitors for severe alopecia areata under different age and product-specific labels [1][3][5]. Each has placebo-controlled evidence for meaningful scalp regrowth in a subset of participants [2][4][6][7].

The trials do not establish which drug is superior. A responsible comparison starts with the correct diagnosis, then keeps age, label restrictions, boxed warnings, monitoring, and the absence of head-to-head evidence visible.

This article is for informational purposes and does not constitute medical advice. Severe alopecia areata should be evaluated and managed by a board-certified dermatologist or another qualified specialist.